Pediatrix Medical Group, Inc DEFA14A, filed Mar 31, 2023
Pediatrix Medical Group, Inc. (MD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| ☐ | Definitive Proxy Statement | |
| ☒ | Definitive Additional Materials | |
| ☐ | Soliciting Material under Rule 14a-12 | |
Pediatrix Medical, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No Fee Required. | |||
| ☐ | Fee paid previously with preliminary materials. | |||
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||
Pediatrix Medical Group, Inc. Important Notice Regarding the Availability of Proxy Materials P.O. BOX 8016, CARY, NC 27512-9903 Shareholders
Meeting to be held on May 11, 2023 For Shareholders of record as of March 13, 2023 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You
cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy materials, and to obtain directions to attend the meeting, go to:
www.proxydocs.com/MD To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy
materials can be distributed by making them available on the internet. For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/MD Have the 12 digit control number located in the shaded box above available when you access the
website and follow the instructions. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper
package in time for this year’s meeting, you must make this request on or before May 01, 2023. To order paper materials, use one of the following methods. INTERNET TELEPHONE * E-MAIL
www.investorelections.com/MD (866) 648-8133 paper@investorelections.com When requesting via the Internet or telephone you will need the 12 digit * If requesting material by
e-mail, please send a blank e-mail with the 12 digit control number (located above) control number located in the shaded box above. in the subject line. No other
requests, instructions OR other inquiries should be included with your e-mail requesting material. Pediatrix Medical Group, Inc. Meeting Type: Annual Meeting of Shareholders Date: Thursday, May 11, 2023
Time: 10:30 AM, Eastern Time Place: Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/MD for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/MD SEE REVERSE FOR FULL
AGENDA
Pediatrix Medical Group, Inc. Annual Meeting of Shareholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2 AND 3 THE BOARD RECOMMENDS THAT AN ADVISORY VOTE ON THE COMPENSATION FOR NAMED EXECUTIVE OFFICERS BE HELD EVERY 1 YEAR. PROPOSAL 1. elect eight Directors, each for a term expiring at the next annual meeting or until a successor has been duly elected and qualified; 1.01 Laura A. Linynsky 1.02 Thomas A. McEachin 1.03 Mark S. Ordan 1.04 Michael A. Rucker 1.05 Guy P. Sansone 1.06 John M. Starcher, Jr. 1.07 James D. Swift, M.D. 1.08 Shirley A. Weis 2. ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2023 fiscal year; 3. conduct an advisory vote regarding the compensation of our named executive officers for the 2022 fiscal year; 4. conduct an advisory vote on the frequency of holding future advisory votes on executive compensation; and 5. consider and act upon such other business as may properly come before the meeting.